Abstract | BACKGROUND: RESULTS: An established chemotherapy-induced painful neuropathy model of two weekly cycles of 10 intraperitoneal (i.p.) injections separated by 5 days rest was used to examine the therapeutic potential of the PARP inhibitor compound 4a. Behavioral testing using von Frey, paw radiant heat, cold plate, and exploratory behaviors were taken at baseline, and followed by testing at 3, 6, and 8 weeks from the beginning of drug treatment. CONCLUSION:
|
Authors | Lauren E Ta, James D Schmelzer, Allan J Bieber, Charles L Loprinzi, Gary C Sieck, Jill D Brederson, Philip A Low, Anthony J Windebank |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 1
Pg. e54161
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 23326593
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Benzimidazoles
- Neuroprotective Agents
- Organoplatinum Compounds
- Poly(ADP-ribose) Polymerase Inhibitors
- veliparib
- Oxaliplatin
- Poly(ADP-ribose) Polymerases
- Cisplatin
|
Topics |
- Animals
- Antineoplastic Agents
(toxicity)
- Benzimidazoles
(administration & dosage, chemical synthesis)
- Cisplatin
(toxicity)
- Humans
- Hyperalgesia
(chemically induced, drug therapy)
- Male
- Mice
- Neuralgia
(chemically induced, drug therapy, metabolism)
- Neuroprotective Agents
(administration & dosage)
- Organoplatinum Compounds
(toxicity)
- Oxaliplatin
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases
(metabolism)
|